HDAC inhibition: A novel therapeutic target for attenuating myocardial ischemia and reperfusion injury by reversing cardiac remodeling

International Journal of Cardiology

Volumn 190, Issue 1, 2015, Pages 126-127

  Wang, Jichun ^a   Hu, Xiaorong ^a   Jiang, Hong ^a  

^a RENMIN HOSPITAL OF WUHAN UNIVERSITY   (China)

Author keywords

Cardiac remodeling; Histone deacetylases (HDACs); Myocardial ischemia and reperfusion injury

Indexed keywords

HISTONE DEACETYLASE; HISTONE DEACETYLASE INHIBITOR; STEM CELL FACTOR;

CARDIAC REMODELING; CLINICAL EFFECTIVENESS; DISEASE ACTIVITY; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG RESPONSE; DRUG TARGETING; ENZYME ACTIVITY; ENZYME ASSAY; ENZYME INHIBITION; HEART DISEASE; HEART MUSCLE FIBROSIS; HEART MUSCLE ISCHEMIA; HEART PROTECTION; HUMAN; LETTER; MOLECULAR PATHOLOGY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; REPERFUSION INJURY; SIGNAL TRANSDUCTION; DRUG DELIVERY SYSTEM; DRUG EFFECTS; HEART VENTRICLE REMODELING; MYOCARDIAL ISCHEMIA; MYOCARDIAL REPERFUSION INJURY; TRENDS;

DRUG DELIVERY SYSTEMS; HISTONE DEACETYLASE INHIBITORS; HUMANS; MYOCARDIAL ISCHEMIA; MYOCARDIAL REPERFUSION INJURY; VENTRICULAR REMODELING;

EID: 84929174331     PISSN: 01675273     EISSN: 18741754     Source Type: Journal    
DOI: 10.1016/j.ijcard.2015.04.172     Document Type: Article

References (15)

1. G. Takemura, M. Nakagawa, H. Kanamori, S. Minatoguchi, H. Fujiwara, Benefits of reperfusion beyond infarct size limitation, Cardiovasc. Res. 83 (2009) 269-276.
2. Y. Sun, Myocardial repair/remodelling following infarction: Roles of local factors, Cardiovasc. Res. 81 (2009) 482-490.
3. C.E. Murdoch, M. Zhang, A.C. Cave, A.M. Shah, NADPH oxidase-dependent redox signalling in cardiac hypertrophy, remodelling and failure, Cardiovasc. Res. 71 (2006) 208-215.
4. M. Xie, Y. Kong,W. Tan, H.May, P.K. Battiprolu, Z. Pedrozo, et al., Histone deacetylase inhibition blunts ischemia/reperfusion injury by inducing cardiomyocyte autophagy, Circulation 129 (2014) 1139-1151.
5. X.J. Yang, E. Seto, Lysine acetylation: Codified crosstalk with other posttranslational modifications, Mol. Cell 31 (2008) 449-461.
6. M. Suzuki-Kurasaki, M. Kurasaki, Y. Kojima, Low molecular weight copper-binding protein in the liver of rats given a single and repeated injections of copper, Res. Commun. Mol. Pathol. Pharmacol. 92 (1996) 299-314.
7. C.L. Antos, T.A. McKinsey, M. Dreitz, L.M. Hollingsworth, C.L. Zhang, K. Schreiber, et al., Dose-dependent blockade to cardiomyocyte hypertrophy by histone deacetylase inhibitors, J. Biol. Chem. 278 (2003) 28930-28937.
8. T.A. McKinsey, Therapeutic potential for HDAC inhibitors in the heart, Annu. Rev. Pharmacol. Toxicol. 52 (2012) 303-319.
9. D.M. Vigushin, R.C. Coombes, Targeted histone deacetylase inhibition for cancer therapy, Curr. Cancer Drug Targets 4 (2004) 205-218.
10. H. Tao, K.H. Shi, J.J. Yang, C. Huang, H.Y. Zhan, J. Li, Histone deacetylases in cardiac fibrosis: Current perspectives for therapy, Cell. Signal. 26 (2014) 521-527.
11. Y.H. Kao, J.P. Liou, C.C. Chung, G.S. Lien, C.C. Kuo, S.A. Chen, et al., Histone deacetylase inhibition improved cardiac functions with direct antifibrotic activity in heart failure, Int. J. Cardiol. 168 (2013) 4178-4183.
12. L. Zhang, B. Chen, Y. Zhao, P.M. Dubielecka, L. Wei, G.J. Qin, et al., Inhibition of histone deacetylase-induced myocardial repair ismediated by c-kit in infarcted hearts, J. Biol. Chem. 287 (2012) 39338-39348.
13. Y. Kong, P. Tannous, G. Lu, K. Berenji, B.A. Rothermel, E.N. Olson, et al., Suppression of class I and II histone deacetylases blunts pressure-overload cardiac hypertrophy, Circulation 113 (2006) 2579-2588.
14. T.C. Zhao, G. Cheng, L.X. Zhang, Y.T. Tseng, J.F. Padbury, Inhibition of histone deacetylases triggers pharmacologic preconditioning effects against myocardial ischemic injury, Cardiovasc. Res. 76 (2007) 473-481.
15. A. Granger, I. Abdullah, F. Huebner, A. Stout, T. Wang, T. Huebner, et al., Histone deacetylase inhibition reduces myocardial ischemia-reperfusion injury in mice, FASEB J. 22 (2008) 3549-3560.